Treatment outcomes of the modified sequential RA-RLT regimen in patients with chronic gastritis

Objective: To evaluate the efficacy and safety of the improved RA-RLT sequential regimen in the treatment of chronic gastritis with Helicobacter pylori infection. Subjects and method: A descriptive cross-sectional study with a prospective intervention and follow-up was conducted on 103 patients diagnosed with chronic gastritis who tested positive for H. pylori. The patients received treatment with the improved RA-RLT sequential regimen for 10 days. Result: The study was conducted on 103 patients with chronic gastritis, with a mean age of 48.6 ± 13.2 years; 52.4% were male, and the majority resided in rural areas (62.1%). The most common clinical symptoms included epigastric pain (89.3%), bloating and belching (71.8%), nausea (41.7%), digestive disorders (26.2%), and fatigue (17.5%). The eradication rate of Helicobacter pylori with the improved RA-RLT sequential regimen was 91.3%, with no significant differences between gender and age groups. The adverse effects were mostly mild and occurred in 40.8% of patients, with the most common being bitter taste (15.5%), diarrhea (11.7%), nausea (8.7%), and headache (4.9%). The eradication rates at 4, 12, and 24 weeks were 91.3%, 92.8%, and 94.0%, respectively. Conclusion: The improved RA-RLT sequential regimen is highly effective in eradicating H. pylori, well tolerated, with minimal side effects, and is suitable for the treatment of chronic gastritis with H. pylori infection.